A recent Pharma IQ survey found that 43% don’t think their organisation effectively oversees clinical trial vendors, while 100% of those asked said they were feeling the pressure of increased regulatory scrutiny of vendor oversight.
So how do we balance effective trial oversight and governance without micromanaging and damaging the sponsor-vendor relationship?
Where do key performance metrics and milestones fit into the oversight strategy?
The 3rd Annual Global Clinical Outsourcing Forum, took place on the 24th-25th April 2012 in Amsterdam, bringing together 20 leading industry experts to guide you through the future of clinical partnerships and facilitate discussion on the issues that matter most to you.
Access key findings of the group work from Breakout Discussion: Effectively Managing Trial Execution and Preventing Overruns through Oversight and Governance Structure here.
|
|
Have Your Say Rate this feature and give us your feedback in the comments section below |